Related Experiment Video

Updated: Jun 1, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma

Makiko Harasawa1, Masanori Yasuda, Takeshi Hirasawa

  • 1Department of Obstetrics and Gynecology, Tokai University School of Medicine.

Acta Histochemica Et Cytochemica
|May 27, 2011
PubMed

Insights

Everolimus effectively targets ovarian clear cell adenocarcinoma (CCA) by inhibiting the mTOR pathway, leading to decreased HIF-1α and VEGF, and inducing apoptosis. This suggests everolimus as a potential anti-cancer therapy for CCA.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian clear cell adenocarcinoma (CCA) is a challenging gynecologic malignancy.
  • The mammalian target of rapamycin (mTOR)-hypoxia inducible factor-1 (HIF-1) pathway plays a role in cancer progression.
  • Understanding the molecular mechanisms of CCA is crucial for developing effective therapies.

Purpose of the Study:

  • To elucidate the mechanism of the mTOR-HIF-1 pathway in human CCA cells.
  • To investigate the effects of everolimus on this pathway and related factors.
  • To evaluate the therapeutic potential of everolimus in a preclinical model of CCA.

Main Methods:

  • Utilized cultured human CCA cell lines treated with everolimus.
  • Analyzed the expression of mTOR, phosphorylated-mTOR (p-mTOR), p-4E-BP1, HIF-1α, VEGF, VHL, and cleaved caspase-3.
  • Assessed tumor growth in nude mice xenografted with CCA cells and treated with everolimus.

Main Results:

  • Everolimus treatment decreased p-mTOR, p-4E-BP1, HIF-1α, and VEGF expression in CCA cells.
  • Everolimus increased VHL expression, suggesting enhanced HIF-1α degradation.
  • Cleaved caspase-3 levels increased, indicating apoptosis induction, and tumor size decreased in treated mice.

Conclusions:

  • Everolimus down-regulates the mTOR pathway and promotes HIF-1α degradation via VHL in CCA.
  • Everolimus induces apoptosis and exhibits anti-tumor activity in a preclinical CCA model.
  • Everolimus demonstrates potential as an anti-cancer therapeutic for ovarian clear cell adenocarcinoma.
Keywords:
anti-cancer therapyclear cell carcinomamTORovaryrapamycin

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...